Creating first in class cachexia therapeutic.

Creating a new standard of care for cancer cachexia patients, enabling greater tolerability of cancer treatment, lengthening life and improving quality of life.


Endevica Bio's lead drug candidate is a peptide therapeutic for treating cachexia due to cancer and other chronic conditions. The company was formed in 2009 to create best in class peptide drug candidates with better safety and efficacy properties than other drugs in the same class.


Endevica Bio's primary molecule TCMCB07 is an MC4R antagonist that has shown efficacy in multiple models of cachexia. Pre-clinical animal trial results show significant lean muscle mass gain (e.g. a reversal of the cachectic condition) during the administration of the drug. The results have been synchronous across multiple cachexia-inducing insult classes. Endevica Bio's technology platform, protected by a family of patents and pending applications, allows us to modify peptides to perform better as drug candidates, with improved half-life, oral activity, and ability to cross the blood-brain barrier.



The company is sponsoring multiple sets of experiments that should result in next-generation cachexia therapeutic intervention strategies with B07. A second molecule (codenamed "Echo") is powered by key platform technologies. Echo showed promising pre-clinical in vivo results in a 4T1 murine triple negative breast cancer model. Human cancer models in nude mice are being tested, with results expected in 2Q 2022.

Major Milestones

NCI/NIH Grant Support

The National Cancer Institute continues to fund our underpinning research in cancer cachexia.


The company has concluded its seed stage financing and anticipates opening a Series A financing round in the summer of 2022.

Intellectual Property

Three issued patent and four pending patents protect our technology platform.

IND Program Begun

An IND enabling toxicology program has begun with an IND anticipated in 2Q 2022.

Scroll to Top